In the October issue of Chest, Glassberg and colleagues published the AETHER study, the second safety trial of allogeneic human MSCs treatment in patients with IPF. In this non-randomised, non-placebo single-centre clinical trial, bone marrow-derived MSCs from two men were cultured and subsequently administered as a single intravenous infusion to nine patients with mild to moderate IPF. No treatmentrelated serious adverse events were reported with infusions up to 2 × 10⁸ cells over a 60-week follow-up period. Two nonstudy related deaths were recorded. Non-serious adverse events unrelated to treatment were reported in most patients (78%), most frequently bronchitis and common cold. Mean absolute declines of 3·0% in % predicted FVC and 5·4% in % predicted DLCO were described in the 60 weeks after infusion, which are below the internationally accepted thresholds representing disease progression.
To our knowledge, this is the third completed phase 1b trial of MSC administration in IPF and the first in-man study with allogeneic bone marrow-derived MSCs. The safety of three types of MSCs have been successfully tested so far in IPF: autologous adipose tissue-derived stromal cells administered endobronchially, intravenous administration of placentaderived MSCs, and bone marrow-derived MSCs.
Despite the wealth of preclinical studies for the use of MSCs in pulmonary fibrosis models, human trials have been delayed following safety risks coupled to a limited knowledge of the mechanism of action of the various stem cell therapies that inevitably hinders the choice of optimal cell therapy. The risks of pulmonary embolism and inappropriate proliferation, differentiation, or homing of the systemically administered cells have been among the foremost concerns associated with stem cell therapies in IPF. Preclinical models have raised questions regarding the pro-fibrotic reprogramming of these cells in the lungs of patients with IPF that could worsen fibrosis due to differentiation to myofibroblasts and macrophages. However, both phase 1 studies of allogeneic healthy donor MSCs, either from placenta or bone marrow, showed only mild and self-limiting adverse effects following intravenous injection of MSCs. The patients were followed up from 6 months to 12 months, and in all trials lung diffusing capacity and 6MWT did not show disease worsening beyond the expected background rate, with respect to disease severity at the date of enrolment. Furthermore, although the numbers of the enrolled patients were low (31 patients), the rate of disease progression observed in all three studies was met with cautious optimism by the investigators of all phase 1b studies.
Considerable reluctance to use the stem cell therapy has been caused by not knowing the exact mechanism of their action. These cells are currently thought to exert their effects through paracrine mediators including soluble factors and MSCderived microvesicles carrying cellular components, including mitochondria, to the compromised cells. Several studies have shown that MSCs' secreted factors resolve inflammation, control immune cell proliferation and function, and have antioxidant properties. However, their precise action at the cellular and molecular level in IPF has only been examined in animals treated with bleomycin or other fibrosis mediators, and usually at early times following the administration of the injurious stimuli. Consequently, this has raised a major concern about the translation of these preclinical MSCs studies into successful clinical trials able to show therapeutic potential. Notably, although promising data are emerging from MSCbased clinical trials in acute respiratory distress syndrome, the likelihood of an effect from therapy for a chronic disease like IPF is uncertain. Furthermore, the possible interaction of the approved antifibrotic and antiproliferative IPF therapies with MSCs treatment should be explored.
The AETHER trial results justify the safety of intravenous infusions of allogeneic bone marrow-derived human MSCs in IPF. Along with the two previous clinical trials, sufficient evidence supports the enrolment of larger patient numbers as well as further dosing studies and testing of different schedules with efficacy endpoints. Several unanswered questions remain including whether to use self or healthy donor cells, their source, and the stem cell potential or character that would be optimal for the treatment of IPF. Unless substantial work is undertaken to fully understand these issues, treatment regimens will remain highly imprecise, speculative, and will hamper the development of the full potential of these experimental therapies, or even worse, lead to possible failure of future efficacy trials.
Few of us like to think of our deaths, or the deaths of those close to us. The inevitability of our end has long been the subject of great works of art, and is a central aspect of religion. However, most people shy away from discussing it, and avoid questions about how to approach it, often until it is too late, and suddenly we find that decisions are being made for us. Those decisions, and the ways that they get made form the central concern of Jessica Nutik Zitter's Extreme Measures: Finding a Better Path to the End of Life. Zitter, a pulmonary and critical care physician who came to be a palliative care specialist after years of watching people on what she describes as the "endof-life conveyor belt", writes movingly and thoughtfully about the choices that confront patients and doctors, whether they realise it or not, and how not confronting these choices leads to worse results than if we engaged with our wishes and made conscious choices about how we want to approach death.
Zitter's on-the-ground description of the way people die in the USA can be pretty harrowing. She recounts examples of patients who physicians know have no chance of recovery being intubated, placed on respirators, and given surgical procedures to reduce the use of machines for feeding and transfusions. In these cases, patients live out their last days sedated to prevent them from harming themselves in their cocoon of machines, isolated from their families, and trapped in the intensive care unit or hospital wards. Many patients are also subjected to invasive last-ditch treatments, or are unresponsive and seldom visited in warehouse-like long-term acute care facilities. The book is interspersed throughout with brief, moving vignettes of patients Zitter has encountered, which illustrate the different ways that people die in modern America and the lessons she has learned from them.
Zitter evangelises for a different way of doing things, one that places the comfort and care of a patient ahead of sustaining life at all costs, even if that means letting the patient die. The book details Zitter's hard-fought attempts to forge a new way for patients who have become accustomed to expect the all-out barrage of medical interventions at the end of life, as well as doctors who-due to both training and inclination-are loathe to not try every treatment available and fear being exposed to legal peril for not doing the utmost. It's a stirring plea for a more humane-and conscientious-approach to dying.
Aaron van Dorn

David Ashbaugh reminisces
For the first description of ARDS see Lancet 1967; 290: 319-23 In 1964, while I was working as codirector of the University of Colorado's (Boulder, CO, USA) first intensive care unit (ICU), I saw my first case of what turned out to be acute respiratory distress syndrome. At the time, I was puzzled about a number of symptoms that I hadn't previously recognised. If the patient had been admitted in the time before intensive care wards and respirators, they would have died without the attending physician knowing why and how. This particular patient was one of the first admitted to a new ICU set up by Dr Thomas Petty and myself. We had just finished residencies in medicine and surgery, respectively, and had lobbied for and obtained the necessary funds and space. We had one primitive respirator to use on patients with respiratory failure. The patient was admitted as a surgical trauma patient to my service, with multiple fractures after an automobile accident. Despite major blood loss, he soon stabilised and had a normal chest x-ray despite a few broken ribs. Over the course of 48 h, he developed respiratory distress and was intubated and put on the respirator, which was run from the hospital wall oxygen supply on a pressure-controlled basis. Despite 100% oxygen and maximum pressure, his condition worsened and fluffy infiltrates appeared in both lungs. He proceeded to die of respiratory failure. The rapid onset fluffy infiltrates, increasing pressures that required us to ventilate the patient, and falling oxygenation puzzled me as I had not seen this in patients before.
Over the following months I saw a couple of similar cases, and went to the library to see what I could find. At the time there was only one reported case of congestive atelectasis following trauma. I consulted with our pathologists and infectious disease specialists and we did find hyaline membranes and alveolar haemorrhage in our patient. Some months later I had borrowed an Engstrom respirator from our anaesthesia department. It was a volume-controlled device and superior to anything we had on our ICU. When a 12-yearold boy presented in the emergency room on a Saturday morning, I was called to come down as he was in severe respiratory distress and coughing up blood after being backed over by a pickup truck. I did an immediate tracheostomy and transferred him to the paediatric care unit. Tom Petty had recently obtained a new blood gas analyser and I learned how to operate it. I spent the morning running up and down four flights of stairs and watching the patient's arterial blood gas deteriorate as we suctioned more and more blood from his tracheotomy. He was attached to the new respirator and I noticed, off to the right hand side, a red dial labelled "end expiratory pressure". I wondered if this might help and dialled in a moderate amount. Within minutes the bleeding slowed and then stopped and the arterial blood gas returned to normal limits. Over the next few days he was weaned from the respirator and made a complete recovery. While this was obviously a case of traumatic pulmonary contusion, it was still a case of severe respiratory distress and positive end expiratory pressure was clearly an effective treatment.
Within 2 years we had collected 12 cases, which included three patients treated with positive end expiratory pressure. Getting the paper published was a struggle, and after four rejections from US-based journals, we submitted it to The Lancet, which not only accepted the paper, but published it on the basis of in-house review within 6 weeks.
David Ashbaugh
